Last reviewed · How we verify

NCT05228756

SCD Fit Homebase Program

Withdrawn NA Last updated 19 October 2022
What this trial tests

NA trial testing Accelerometer in Cardiovascular Diseases. Withdrawn.

Timeline
1 November 2022
Primary endpoint
1 December 2023
1 December 2023

Quick facts

Lead sponsorUniversity of Alabama at Birmingham
PhaseNA
StatusWithdrawn
Study typeINTERVENTIONAL
Allocationna
Designsingle group
Maskingnone
Primary purposeother
Start date1 November 2022
Primary completion1 December 2023
Estimated completion1 December 2023

Drugs / interventions tested

Conditions studied

Sponsor

University of Alabama at Birmingham

Who can join

18 and older, any sex, with Cardiovascular Diseases or Sickle Cell Disease. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this project is to develop novel approaches to promote health and longevity while enhancing quality of life among persons with Sickle cell disease (SCD). Therefore, investigators are aiming to adapt an evidence-based exercise intervention for adults with SCD informed by culturally- relevant and biologic factors.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Accelerometer

Trials testing the same drug.

Other recruiting trials for Cardiovascular Diseases

Currently open trials in the same condition.

Other University of Alabama at Birmingham trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05228756.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing